KYMERA THERAPEUTICS I
43.47
08-October-24 13:01:20
15 minutes delayed
Stocks
+1.26
+2.99%
Today's range
42.41 - 43.62
ISIN
N/A
Source
NASDAQ
-
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire
-
22 Jun 2023 08:30:00 By Nasdaq GlobeNewswire
-
09 Jun 2023 18:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Participate in Upcoming June Investor Conference
01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire
-
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
22 May 2023 07:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
19 May 2023 07:00:00 By Nasdaq GlobeNewswire
-
18 May 2023 07:00:01 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
04 May 2023 07:00:01 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
11 Apr 2023 07:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire
-
23 Feb 2023 07:00:01 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
01 Feb 2023 07:00:00 By Nasdaq GlobeNewswire
-
10 Jan 2023 07:00:00 By Nasdaq GlobeNewswire
-
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
04 Jan 2023 07:00:02 By Nasdaq GlobeNewswire
-
03 Jan 2023 07:00:00 By Nasdaq GlobeNewswire